Protease‐activated receptor‐2 suppresses interleukin (<scp>IL</scp>)‐10 expression in B cells via upregulating Bcl2L12 in patients with allergic rhinitis

Xue, Jinmei; Yang, Litao; Yang, Gui; Geng, Xinyu; Liu, Zhiqiang; Wang, Shuai; Zhao, Hailiang; Zhao, Changqing; Yang, Ping‐Chang

doi:10.1111/all.13186

Cited by 22 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was lately found that Bcl2L12 was also involved in the development of other types of cancer with its anti‐apoptotic activities . Further reports indicate that Bcl2L12 is associated with the immune deregulation . The present study has added novel information to this study field that Bcl2L12 regulates CD4 + T cell activities by compromising the apoptosis machinery to induce defects of apoptosis in CD4 + T cells.…”

Section: Discussionmentioning

confidence: 62%

“…20 Further reports indicate that Bcl2L12 is associated with the immune deregulation. 12,13 The present study has added novel information to this study field that Bcl2L12 regulates CD4 + T cell activities by compromising the apoptosis machinery to induce defects of apoptosis in CD4 + T cells. On the other hand, the defects of apoptosis in CD4 + T cells may be also a result of Th2 polarization because IL-5 can increase the expression of Bcl2L12 in CD4 + T cells.…”

Section: Discussionmentioning

confidence: 82%

“…The phenomenon implies the expression and functions of some regulatory factors of apoptosis in CD4 + T cells may be unusually changed. Our recent studies revealed that Bcl2‐like protein‐12 (Bcl2L12) was aberrantly higher in patients with AR and patients with intestinal inflammation . Bcl2L12 is an anti‐apoptosis protein .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Interleukin-5 induces apoptotic defects in CD4+ T cells of patients with allergic rhinitis

Luo

Wang

et al. 2019

Journal of Leukocyte Biology

View full text Add to dashboard Cite

T helper (Th)2 polarization plays an important role in the pathogenesis of allergic diseases; the underlying mechanism remains to be further investigated. B cell lymphoma protein‐2 like protein‐12 (Bcl2L12) has the anti‐apoptotic function. This study aims to elucidate the contribution of Bcl2L12 to Th2 polarization in patients with allergic rhinitis (AR). In this study, human CD4+ T cells were isolated from blood samples collected from AR patients and healthy control (HC) subjects. The immune response profiles of CD4+ T cells were analyzed by immunologic approaches. The results showed that AR CD4+ T cells (CD4+ T cells collected from AR patients) showed defects of apoptosis. The expression of FasL in AR CD4+ T cells was lower than that of HC CD4+ T cells. Serum IL‐5 levels were negatively correlated with the expression of FasL in AR CD4+ T cells. Exposure of CD4+ T cells to IL‐5 in the culture suppressed the expression of FasL and increased the expression of Bcl2L12. IL‐5 increased the levels of Bcl2L12 in CD4+ T cells, the latter bound to the FasL promoter to prevent FasL gene transcription. Inhibition of Bcl2L12 restored the apoptosis machinery in AR CD4+ T cells. In conclusion, overexpression of Bcl2L12 in CD4+ T cells compromises the apoptosis machinery; the latter can be restored by inhibition of Bcl2L12. BcL2L12 in CD4+ T cells may be a novel target for the treatment of AR and other allergic disorders.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

Interleukin-5 induces apoptotic defects in CD4+ T cells of patients with allergic rhinitis

Luo

Wang

et al. 2019

Journal of Leukocyte Biology

View full text Add to dashboard Cite

show abstract

“…The activation of protease-activated receptor (PAR)-2 on B cells inhibits IL-10 expression in peripheral B cells via upregulating Bcl2-like protein-12 (Bcl2L12). 45 Novel therapeutic candidates for the treatment of AR have been developed that compete with Bcl2L12 and restore IL-10 production, as recently demonstrated in a mouse model treated with Bcl2L12 shRNA liposomes ( Figure 2). Forkhead box protein-3 (Foxp3) is a key transcription factor of T regulatory (Treg) cells implicated in immune tolerance.…”

Section: Novel Hi G Hli G Hts On Mechanis Ms Of Allerg I C D Is E Amentioning

confidence: 97%

Highlights and recent developments in airway diseases in EAACI journals (2018)

Bousquet

Akdiş

Grattan

et al. 2019

Allergy

View full text Add to dashboard Cite

The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: Allergy, Pediatric Allergy and Immunology, and Clinical and Translational Allergy. EAACI's major goals include supporting the promotion of health, in which the prevention of allergy and asthma plays a critical role, and disseminating the knowledge of allergic disease to all stakeholders. In 2018, the remarkable progress in the identification of basic mechanisms of allergic and respiratory diseases as well as the translation of these findings into clinical practice were observed. Last year's highlights include publication of EAACI guidelines for allergen immunotherapy, many EAACI Position Papers covering important aspects for the specialty, better understanding of molecular and cellular mechanisms, identification of biomarkers for disease prediction and progress monitoring, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, introduction of new drugs to the clinics, recently completed phase three clinical studies, and publication of a large number of allergen immunotherapy studies and meta‐analyses.

show abstract

“…48 It was reported that activation of protease-activated receptor (PAR)-2 promotes the suppression of IL-10 in B cells, which can be inhibited by treating B cells with Bcl2-like protein 12 (Bcl2L12) shRNA-carrying liposomes. 53 These data suggest that regulation of Bcl2L12 may be a novel approach in the treatment for AR.…”

mentioning

confidence: 90%

Recent developments and highlights in allergic rhinitis

Meng

Wang

Zhang

2019

Allergy

135

105

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a disease with high prevalence all over the world and therefore needs to be thoroughly investigated and treated accordingly. The mechanisms underlying the pathology and treatment of AR have been widely studied, but many aspects remain unclear and warrant further investigations. This review presents an overview of recently published papers highlighting the risk factors, mechanisms, and treatment of AR. Additionally, recent studies discussing the role of single nucleotide polymorphism, DNA methylation, regulatory B cells, group 2 innate lymphoid cells, immunotherapy, and biologics in AR are also covered. K E Y W O R D Sallergic rhinitis, biologics, epigenetics, risk factors, treatment | 2321 MENG Et al.

show abstract

Protease‐activated receptor‐2 suppresses interleukin (IL)‐10 expression in B cells via upregulating Bcl2L12 in patients with allergic rhinitis

Abstract: Activation of PAR2 inhibits the expression of IL-10 in B cells, which can be reversed by treating B cells with Bcl2L12 shRNA-carrying liposomes. The data suggest that regulation of Bcl2L12 may be a novel approach in the treatment for AR.

Cited by 22 publications

References 23 publications

Interleukin-5 induces apoptotic defects in CD4+ T cells of patients with allergic rhinitis

Interleukin-5 induces apoptotic defects in CD4+ T cells of patients with allergic rhinitis

Highlights and recent developments in airway diseases in EAACI journals (2018)

Recent developments and highlights in allergic rhinitis

Contact Info

Product

Resources

About